A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
Phase 1
Recruiting
- Conditions
- HyperuricemiaHypouricemia, Renal
- Interventions
- Other: Placebo matching IG3018
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Intelligem Therapeutics Australia Pty Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06310967
- Locations
- 🇦🇺
Emeritus Research Pty Ltd -Sydney, Botany, New South Wales, Australia
🇦🇺Pendlebury Research Pty Ltd T/A Novatrials, Kotara, New South Wales, Australia
🇦🇺Emeritus Research Pty Ltd -Melbourne, Camberwell, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath